Pharmaceuticals News and Research

RSS

AlzeCure deploys Vortex tool to develop novel therapies for Alzheimer's disease

Dotmatics, a leading provider of scientific informatics solutions and services to the pharmaceutical and biotechnology industries, announced today that the research foundation AlzeCure, has deployed and integrated the data visualization and analysis tool Vortex. AlzeCure is a novel innovative drug discovery unit that will use Vortex to help in the quest to discover and develop novel therapies for the treatment of Alzheimer's disease and other neurodegenerative disorders.

11 Dec 2013

Crealta to acquire all assets of Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. ("Savient") announced that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million.

11 Dec 2013

TPP negotiations on tobacco control measures fail to reach agreement

Negotiations on the Trans Pacific Partnership (TPP) failed to reach a final agreement yesterday in Singapore. This is an interim victory for campaigns by the Center for Policy Analysis on Trade and Health (CPATH) and allies to extricate tobacco control measures and other public health protections from nullification by corporate trade rules.

11 Dec 2013

Acid-inhibiting medications linked with increased risk for vitamin B12 deficiency

Use for 2 or more years of proton pump inhibitors and histamine 2 receptor antagonists (two types of acid-inhibiting medications) was associated with a subsequent new diagnosis of vitamin B12 deficiency, according to a study appearing in the December 11 issue of JAMA.

11 Dec 2013

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research suggests.

11 Dec 2013

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.

11 Dec 2013

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.

11 Dec 2013

Acetylon Pharmaceuticals presents positive preclinical data for selective HDAC1/2 inhibitors at ASH meeting

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data for its selective HDAC1/2 inhibitors for the treatment of sickle cell disease (SCD) and β-thalassemia (bT) were presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA.

11 Dec 2013

Navidea receives Fast Track designation for Lymphoseek injection

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

11 Dec 2013

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

Avanir Pharmaceuticals, Inc. today announced that PRIME, its phase II clinical trial of the investigational drug AVP-923 (dextromethorphan / quinidine) for the treatment of central neuropathic pain in patients with multiple sclerosis did not meet the primary efficacy endpoint.

10 Dec 2013

Study links vitamin B12 deficiency to acid-suppressing medications

Long-term use of commonly prescribed heartburn and ulcer medications is linked to a higher risk of vitamin B12 deficiency, according to a new study published online in the Journal of the American Medical Association.

10 Dec 2013

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

The need for biosimulation is primarily to do with the very high attrition rate in drug development and especially in the development of drugs for the central nervous system.

10 Dec 2013

Computational predictive toxicology services available in SafeBridge Consultants

SafeBridge Consultants, Inc., a division of Trinity Consultants, Inc., Dallas, TX, with offices in Mountain View, CA, New York, NY, and Liverpool, UK, announces the availability of computational predictive toxicology services to the biopharmaceutical and chemical industry.

10 Dec 2013

Many Americans still tend to avoid addressing own end-of-life issues

During the past two decades, high-profile legal cases surrounding end-of-life decisions have received widespread attention in the United States, prompting increased media focus and numerous debates on the subject.

10 Dec 2013

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.

10 Dec 2013

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Takeda Pharmaceutical Company Limited today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

10 Dec 2013

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data of selective HDAC6 inhibitor, ricolinostat (ACY-1215), in models of lymphoma were presented today in an oral presentation by Dr. Jennifer Amengual, Assistant Professor of Medicine & Experimental Therapeutics, Columbia University Medical Center.

10 Dec 2013

IBN and IBM discover new medical application for converted PET bottles

Researchers at Singapore's Institute of Bioengineering and Nanotechnology (IBN) and California's IBM Research - Almaden (IBM) have discovered a new, potentially life-saving application for polyethylene terephthalate (PET), which is widely used to make plastic bottles.

10 Dec 2013

CRAB CTC enrolls first patient into inaugural cancer clinical trial

Cancer Research And Biostatistics today announced enrollment of the first patient into the inaugural clinical trial sponsored by its Clinical Trials Consortium. The CRAB CTC mission is to ensure rapid clinical testing of new and innovative cancer treatments, and is focusing on lung cancer as its first target. By engaging frontline treating oncologists to push the boundaries of patient care, the aim is to improve the standard of care and extend overall survival.

9 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

Pharmaceuticals News and Research

AlzeCure deploys Vortex tool to develop novel therapies for Alzheimer's disease

Crealta to acquire all assets of Savient Pharmaceuticals

TPP negotiations on tobacco control measures fail to reach agreement

Acid-inhibiting medications linked with increased risk for vitamin B12 deficiency

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

GW Pharmaceuticals receives U.S. patent for treating glioma

Acetylon Pharmaceuticals presents positive preclinical data for selective HDAC1/2 inhibitors at ASH meeting

Navidea receives Fast Track designation for Lymphoseek injection

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

Study links vitamin B12 deficiency to acid-suppressing medications

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

Computational predictive toxicology services available in SafeBridge Consultants

Many Americans still tend to avoid addressing own end-of-life issues

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

IBN and IBM discover new medical application for converted PET bottles

CRAB CTC enrolls first patient into inaugural cancer clinical trial

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence